The therapeutic potential of correcting abnormalities in
SPs has already been demonstrated in the lower airways. The
correction of SP-D deficiencies with topical SP-D reverses
emphysema, pulmonary lipidosis, and macrophage infiltrations
in diseased mice.15 Gesche et al found that human (rh)
KGF, betamethasone, or their combination treatment increased
secreted surfactant phosphatidylcholines in neonatal
rats with lung injuries.16 Furthermore, topical SP-A and SP-D
decreased IgE and eosinophilia in mouse models of allergic
bronchopulmonary aspergillosis.17 Because allergic bronchopulmonary
aspergillosis is very similar to allergic fungal
rhinosinusitis and can be considered its counterpart in the
lower airway, this could lead to future therapeutic options for
difficult to treat sinus disease, as Tan et al found that the
surfactant does not appear to elicit cellular toxicity using an in
vitro explant model
The therapeutic potential of correcting abnormalities inSPs has already been demonstrated in the lower airways. Thecorrection of SP-D deficiencies with topical SP-D reversesemphysema, pulmonary lipidosis, and macrophage infiltrationsin diseased mice.15 Gesche et al found that human (rh)KGF, betamethasone, or their combination treatment increasedsecreted surfactant phosphatidylcholines in neonatalrats with lung injuries.16 Furthermore, topical SP-A and SP-Ddecreased IgE and eosinophilia in mouse models of allergicbronchopulmonary aspergillosis.17 Because allergic bronchopulmonaryaspergillosis is very similar to allergic fungalrhinosinusitis and can be considered its counterpart in thelower airway, this could lead to future therapeutic options fordifficult to treat sinus disease, as Tan et al found that thesurfactant does not appear to elicit cellular toxicity using an invitro explant model
การแปล กรุณารอสักครู่..